The Food and Drug Administration (FDA) recently approved Keytruda (pembrolizumab) plus chemoradiotherapy (CRT) for the treatment of patients with stages 3 to 4A cervical cancer. The first approval of ...
Recent research showed that Keytruda plus chemotherapy was superior to placebo plus chemotherapy in GI cancers, although the results were not considered statistically significant. The treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback